Clinical use of naltrexone (EN-1639A): Part I: Safety and efficacy in pilot studies.
D000328:Adult; D000553:Ambulatory Care; D004341:Drug Evaluation; D005260:Female; D006556:Heroin Dependence / Q000188:drug therapy*; D006801:Humans; D007880:Legislation, Drug; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000031:analogs & derivatives*; D009271:Naltrexone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced; D009519:New York City; D010865:Pilot Projects; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control; D014481:United States
D009270:Naloxone; D009271:Naltrexone